EDIT Editas Medicine, Inc. Stock Quote

EDIT [NASD]

Index	-	P/E	-	EPS (ttm)	-2.55	Insider Own	0.10%	Shs Outstand	67.88M	Perf Week	-4.39%
Market Cap	4.21B	Forward P/E	-	EPS next Y	-3.48	Insider Trans	-3.62%	Shs Float	66.83M	Perf Month	5.37%
Income	-166.70M	PEG	-	EPS next Q	-0.82	Inst Own	74.80%	Short Float	10.13%	Perf Quarter	76.14%
Sales	81.10M	P/S	51.87	EPS this Y	26.00%	Inst Trans	-0.13%	Short Ratio	3.38	Perf Half Y	40.44%
Book/sh	9.04	P/B	6.99	EPS next Y	-0.30%	ROA	-24.60%	Target Price	50.75	Perf Year	93.27%
Cash/sh	9.17	P/C	6.89	EPS next 5Y	-	ROE	-32.00%	52W Range	27.01 - 99.95	Perf YTD	-9.86%
Dividend	-	P/FCF	-	EPS past 5Y	0.70%	ROI	-34.30%	52W High	-36.77%	Beta	1.91
Dividend %	-	Quick Ratio	9.30	Sales past 5Y	123.40%	Gross Margin	-	52W Low	133.99%	ATR	4.40
Employees	235	Current Ratio	9.30	Sales Q/Q	-96.30%	Oper. Margin	-	RSI (14)	53.26	Volatility	6.19% 6.66%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-91.10%	Profit Margin	-	Rel Volume	1.07	Prev Close	61.00
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 04 BMO	Payout	-	Avg Volume	2.00M	Price	63.20
Recom	2.70	SMA20	-1.51%	SMA50	15.01%	SMA200	25.14%	Volume	2,149,475	Change	3.61%

Sep-10-21

Upgrade

Oppenheimer

Perform → Outperform

$42 → $80

Aug-09-21

Upgrade

Truist

Hold → Buy

$45 → $80

Aug-05-21

Upgrade

Evercore ISI

Underperform → Outperform

$20 → $60

Jun-04-21

Resumed

Robert W. Baird

Outperform

$44

May-04-21

Initiated

RBC Capital Mkts

Sector Perform

$40

Apr-16-21

Initiated

Goldman

Sell

$20

Mar-22-21

Initiated

Credit Suisse

Outperform

$58

Mar-01-21

Downgrade

Barclays

Overweight → Equal Weight

$46

Feb-26-21

Downgrade

Truist

Buy → Hold

$45

Jan-19-21

Downgrade

Morgan Stanley

Equal-Weight → Underweight

$64 → $45

Jan-07-21

Downgrade

Raymond James

Outperform → Mkt Perform

Dec-10-20

Upgrade

Wells Fargo

Equal Weight → Overweight

$69

Nov-03-20

Initiated

Robert W. Baird

Underperform

$14

Jun-18-20

Resumed

SunTrust

Buy

$45

Feb-21-20

Initiated

Wells Fargo

Equal Weight

$28

Apr-12-19

Initiated

Evercore ISI

Outperform

Oct-10-18

Initiated

Guggenheim

Neutral

Sep-21-18

Initiated

Raymond James

Outperform

$40

May-15-18

Reiterated

Chardan Capital Markets

Buy

$72.50 → $55

Feb-13-18

Initiated

CLSA

Underperform

Sep-13-21 08:00AM	Aadi Bioscience Appoints Emma Reeve to its Board of Directors GlobeNewswire
Sep-09-21 12:37PM	3 Red-Hot Healthcare Stocks to Buy in September Motley Fool
Sep-08-21 09:00AM	Editas Medicine Names Emma Reeve to Board of Directors GlobeNewswire
Sep-07-21 04:00PM	Initial Clinical Data from Editas Medicines BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September GlobeNewswire
Sep-03-21 11:31AM	Why Is Editas (EDIT) Up 33.8% Since Last Earnings Report? Zacks -6.43%
07:30AM	Forget About the Genomic Revolution, the Proteomic Revolution Is Coming InvestorPlace
Sep-02-21 08:00AM	Editas Medicine to Participate in Upcoming Investor Conferences GlobeNewswire +9.42%
Sep-01-21 08:15AM	Is Editas Medicine (NASDAQ:EDIT) A Risky Investment? Simply Wall St.
Aug-23-21 07:00AM	25 Stocks Moving in Monday's Pre-Market Session Benzinga +8.25%
06:11AM	Editas Medicine Unveils Preclinical Data From New Gene Editing Technology Benzinga
Aug-20-21 04:20PM	Editas Medicine Presents Data on New SLEEK Gene Editing Technology at Cold Spring Harbor Laboratorys Genome Engineering: CRISPR Frontiers Meeting GlobeNewswire
Aug-17-21 10:21AM	Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why Zacks
Aug-12-21 05:52AM	Will Moderna Buy Editas Medicine to Jump Into Gene Editing? Motley Fool
Aug-09-21 06:05PM	Why Editas Medicine Beat the Market on Monday Motley Fool
Aug-05-21 12:43PM	Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y Zacks +18.37%
Aug-04-21 05:30PM	Editas Medicine, inc (EDIT) Q2 2021 Earnings Call Transcript Motley Fool +9.36%
08:15AM	Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM	Editas Medicine Announces Second Quarter 2021 Results and Business Updates GlobeNewswire
Aug-02-21 09:29AM	Editas (EDIT) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-30-21 05:50PM	Editas Medicine (EDIT) Stock Moves -0.1%: What You Should Know Zacks
09:35AM	10 Best Up and Coming Stocks to Invest In Insider Monkey
Jul-29-21 09:00AM	Editas Medicine and IDT Announce Publication in Nature Communications of Research Data Supporting the Use of Optimized AsCas12a Nuclease Variant, Alt-R A.s. Cas12a (Cpf1) Ultra, in Researching the Potential of Gene-Edited Cell Medicines GlobeNewswire
Jul-28-21 07:00AM	Editas Medicine to Host Conference Call Discussing Second Quarter 2021 Results and Corporate Update GlobeNewswire +6.39%
Jul-26-21 09:00AM	Editas Medicine Names Bruce E. Eaton, Ph.D., as Executive Vice President and Chief Business Officer GlobeNewswire
Jul-23-21 07:01AM	5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021 Motley Fool -5.05%
Jul-22-21 02:25PM	Editas Medicine Stock Shows Improved Relative Strength Rating Investor's Business Daily
Jul-19-21 08:25PM	Hedge Funds Are Crazy About Editas Medicine, Inc. (EDIT) Insider Monkey
Jul-18-21 04:00AM	Do Institutions Own Editas Medicine, Inc. (NASDAQ:EDIT) Shares? Simply Wall St.
Jul-16-21 11:02AM	Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week Motley Fool
Jul-15-21 08:19AM	After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding Motley Fool
Jul-09-21 04:04PM	A Comprehensive Guide to Genomic ETFs Zacks +5.08%
Jul-07-21 08:34AM	Do Options Traders Know Something About Editas Medicine (EDIT) Stock We Don't? Zacks -5.07%
Jul-02-21 12:48PM	Here's What Drove Gene Editing Stocks Higher This Week Motley Fool
Jun-29-21 09:55AM	3 Biotech Stocks Up on Intellia's CRISPR Therapy Study Data Zacks
Jun-28-21 04:25PM	Cathie Wood Funds Jump as Gene Editing Edges Closer to Reality Bloomberg +5.04%
12:17PM	Why Editas Medicine Stock Is Jumping Today Motley Fool
05:34AM	Intellia Soars On Positive Results In Gene-Editing Treatment Investing.com
Jun-25-21 06:01AM	Why Editas Medicine Stock Is Jumping 13.9% This Week Motley Fool
Jun-24-21 11:00AM	Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study Zacks +8.06%
Jun-23-21 07:00AM	Editas Medicine Announces Enrollment of the First Pediatric Cohort in the BRILLIANCE Clinical Trial of EDIT-101 for the Treatment of LCA10 Following IDMC Endorsement GlobeNewswire
Jun-15-21 04:01PM	Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer GlobeNewswire -8.90%
Jun-14-21 09:00AM	Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth GlobeNewswire
Jun-11-21 06:00AM	Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress GlobeNewswire
Jun-07-21 07:11AM	What's the Best Way to Invest in Genetics Stocks? Motley Fool +5.46%
Jun-05-21 08:08AM	Is Editas the Best Genetics Stock to Buy? Motley Fool
Jun-04-21 11:31AM	Why Is Editas (EDIT) Down 2.9% Since Last Earnings Report? Zacks
Jun-03-21 03:14AM	Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation Simply Wall St.
May-17-21 06:15PM	Earnings Roundup: General Motors, Editas Medicine, Activision Blizzard, Match Group Motley Fool
May-11-21 08:00AM	11 Plunging Stocks Are Badly Burning Cathie Wood's ARK Invest Investor's Business Daily
May-05-21 04:30PM	Editas Medicine, Inc. (EDIT) Q1 2021 Earnings Call Transcript Motley Fool
02:46PM	What Really Mattered With Editas Medicine's Q1 Update Motley Fool
11:05AM	Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat Zacks
08:20AM	Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:00AM	Editas Medicine Announces First Quarter 2021 Results and Update GlobeNewswire
06:59AM	Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer GlobeNewswire
06:15AM	Editas Medicine, Inc. to Host Earnings Call ACCESSWIRE
May-04-21 09:00AM	Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting GlobeNewswire
May-03-21 05:59PM	Checking In on 3 Stock Samplers Motley Fool
May-01-21 07:11AM	Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting GlobeNewswire
Apr-28-21 07:01AM	Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update GlobeNewswire
Apr-27-21 07:52AM	Editas (EDIT) to Report Q1 Earnings: Whats in the Cards? Zacks
Apr-19-21 03:31AM	Did You Miss Editas Medicine's (NASDAQ:EDIT) 44% Share Price Gain? Simply Wall St.
Apr-16-21 03:51PM	CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today InvestorPlace -15.40%
03:31PM	Nasdaq Stays Flat as Workhorse Drives Higher, Editas Sinks Motley Fool
02:39PM	Why Editas Medicine Stock Is Getting Crushed Today Motley Fool
02:05PM	Goldman Sachs Just Put Editas Stock on Sale Buy the Dip InvestorPlace
07:05AM	Editas Medicine Falls as Goldman Sachs Initiates the Stock at Sell TheStreet.com
06:30AM	3 Biotech Stocks Ripe for Spring Portfolio Cleaning Motley Fool
Apr-07-21 10:58AM	An End to This Rare Syndrome Could Be an Opportunity for Investors Motley Fool -5.25%
Apr-02-21 08:06AM	Here's the Holy Grail of Gene Editing Motley Fool
Mar-29-21 05:52AM	3 Stocks More Than 25% Off Their 2021 Highs That Could Still Make You Rich Motley Fool
Mar-27-21 11:31AM	Why Is Editas (EDIT) Down 9.6% Since Last Earnings Report? Zacks
Mar-11-21 12:06PM	bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study Zacks
Mar-09-21 11:52AM	Why Editas Medicine Stock Is Bouncing Back Today Motley Fool +11.82%
Mar-06-21 10:12AM	Should Investors Be Worried About Editas' Share Decline? Motley Fool
Mar-04-21 11:36PM	The Chairman of Editas Medicine, Inc. (NASDAQ:EDIT), James Mullen, Just Bought 250% More Shares Simply Wall St. -6.42%
04:08PM	Why Editas Medicine Stock Sank Today Motley Fool
Feb-27-21 09:23AM	15 Fastest Growing Biotech Companies in the US Insider Monkey
Feb-26-21 09:04AM	Editas (EDIT) Misses on Q4 Earnings, Beats on Revenues Zacks
Feb-25-21 01:00PM	Editas Medicine, Inc. (EDIT) Q4 2020 Earnings Call Transcript Motley Fool -9.94%
07:00AM	Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update GlobeNewswire
05:45AM	Editas Medicine, Inc. to Host Earnings Call ACCESSWIRE
Feb-23-21 02:29PM	Here's Why Editas Medicine Dropped Today Motley Fool -6.26%
Feb-20-21 09:03AM	Will Editas Medicine's CEO Change Help or Hurt? Motley Fool
Feb-18-21 04:02PM	Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update GlobeNewswire
Feb-17-21 06:30AM	Where Will Editas Medicine Be in 5 Years? Motley Fool
Feb-12-21 05:45PM	Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know Zacks
Feb-10-21 04:42PM	Why Editas Medicine Stock Sank Today Motley Fool -11.42%
Feb-08-21 08:00AM	Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer GlobeNewswire +8.88%
Feb-05-21 06:10AM	Better Buy: CRISPR Therapeutics vs. Editas Medicine Motley Fool
Feb-04-21 05:45PM	Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know Zacks
Jan-26-21 06:30AM	Is Editas Medicine a Buy? Motley Fool -7.32%
Jan-25-21 05:45PM	Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know Zacks
06:01AM	Why I'm Betting Big on This 1 Megatrend Motley Fool
Jan-24-21 07:10AM	Where to Invest $1 Million Right Now Motley Fool
Jan-20-21 11:31PM	Editas Medicine, Inc. (NASDAQ:EDIT) Analysts Just Slashed Next Year's Revenue Estimates By 31% Simply Wall St.
10:30PM	Editas Medicine Announces Pricing of Offering of Common Stock GlobeNewswire
Jan-19-21 04:01PM	Editas Medicine Announces Offering of Common Stock GlobeNewswire -5.29%
Jan-18-21 08:41AM	Editas (EDIT) Up More Than 100% in Past 3 Months: Here's Why Zacks
Jan-15-21 06:12PM	7 CRISPR Stocks for the Future of Medicine InvestorPlace

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBERTSON MICHELLE	Chief Financial Officer	Aug 09	Option Exercise	30.65	2,500	76,625	31,235	Aug 10 04:33 PM
ROBERTSON MICHELLE	Chief Financial Officer	Aug 09	Sale	60.00	2,500	150,000	28,735	Aug 10 04:33 PM
Hopfield Jessica	Director	Mar 03	Buy	45.51	5,800	263,970	22,700	Mar 05 04:13 PM
MULLEN JAMES C	CEO	Mar 02	Buy	46.27	25,000	1,156,800	35,000	Mar 04 04:17 PM
Collins Cynthia	CEO	Feb 09	Sale	66.65	1,262	84,112	43,760	Feb 10 04:26 PM
ROBERTSON MICHELLE	Chief Financial Officer	Jan 12	Sale	78.27	1,568	122,727	18,432	Jan 13 04:11 PM
Albright Charles	EVP/Chief Scientific Officer	Dec 15	Option Exercise	16.51	10,000	165,100	34,907	Dec 17 06:58 PM
Albright Charles	EVP/Chief Scientific Officer	Dec 15	Sale	63.22	10,000	632,156	24,907	Dec 17 06:58 PM
Albright Charles	EVP/Chief Scientific Officer	Dec 09	Option Exercise	16.51	10,000	165,100	34,907	Dec 11 04:14 PM
Albright Charles	EVP/Chief Scientific Officer	Dec 09	Sale	45.00	10,000	450,000	24,907	Dec 11 04:14 PM
Albright Charles	EVP/Chief Scientific Officer	Dec 07	Option Exercise	16.51	20,000	330,200	44,907	Dec 08 04:12 PM
Albright Charles	EVP/Chief Scientific Officer	Dec 07	Sale	40.02	20,000	800,400	24,907	Dec 08 04:12 PM
Albright Charles	EVP/Chief Scientific Officer	Nov 09	Sale	31.21	228	7,116	24,907	Nov 10 04:13 PM
Albright Charles	EVP/Chief Scientific Officer	Oct 15	Sale	31.39	3,000	94,170	25,135	Oct 16 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience